Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly
predict tumor-agnostic efficacy of TRK inhibition,,,,,,–. With the recent approval of the first …

Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …

The microenvironment influences cancer drug response and sustains resistance to
therapies targeting receptor-tyrosine kinases. However, if and how the tumor …

Targeted cancer therapies have produced substantial clinical responses, but most tumors
develop resistance to these drugs. Here, we describe a pharmacogenomic platform that …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Neovascular age-related macular degeneration (nAMD) is a major cause of visual
impairment and blindness. Anti-vascular endothelial growth factor (VEGF) agents, such as …